hit counter
ATA Inc. (ATAI) Stock News Sentiment & Price - Sentifly
ATAI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ATA Inc. (ATAI)

ATAI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ATAI Latest news
InvestorPlace
Positive
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
2021-11-11 10:42

Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.

GlobeNewsWire
Neutral
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
2021-11-08 08:30

NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update.

GlobeNewsWire
Neutral
atai Life Sciences to Participate in Upcoming November Investor Conferences
2021-11-05 16:30

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:

Benzinga
Positive
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStop
2021-11-02 16:43

Psychedelics have picked up more and more momentum on Wall Street, with famed investors such as Kevin O'Leary and Peter Thiel recognizing the potential in the psych drug industry.  Psychedelic drugs, such as psilocybin mushrooms and LSD, were once seen merely as a way for college students and concert goers to escape reality or at least enhance it.

The Motley Fool
Positive
These 4 Psychedelic Biotech Stocks Are Leading the Pack
2021-10-26 06:50

Their clinical programs and research-enabling technologies both surpass the competition.

GlobeNewsWire
Neutral
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change
2021-10-19 07:00

atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care

Benzinga
Neutral
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health Disorders
2021-10-11 15:45

Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression and other mental health indications.

Benzinga
Positive
Atai Life Launches Depression-Focused Firm
2021-10-11 10:42

Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout.  PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications.

GlobeNewsWire
Neutral
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx's Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
2021-09-15 08:10

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“Loan Agreement”) with strategic partner IntelGenx Technologies Corp. (“IntelGenx”) to support IntelGenx's conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock Exchange (“TSX”). Completion of the uplisting and the commencement of trading of IntelGenx's common shares, 8% convertible debentures with a maturity date of June 30, 2022, and share purchase warrants expiring on February 11, 2023 is subject to the satisfaction by IntelGenx of all of the final conditions of listing.

Benzinga
Positive
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog Arketamine
2021-09-14 14:59

Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a proprietary formulation of arketamine that could have a similar therapeutic action to ketamine in the treatment of depression, with less dissociative effects.

Loading more news...